Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese

Neuropsychobiology

Volumn 47, Issue 4, 2003, Pages 178-181

  Chiu, Hsien Jane ^a,b   Wang, Ying Chieh ^c   Liou, Ying Jay ^c   Lai, I Ching ^c   Chen, Jen Yeu ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Provincial Tao Yuan Hospital   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

Author keywords

N Methyl D aspartate receptor 2b subunit; Polymorphism; Schizophrenia, treatment refractory

Indexed keywords

CLOZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CLOZAPINE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, N-METHYL-D-ASPARTATE; RISK FACTORS; SCHIZOPHRENIA;

EID: 0038009306     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071211     Document Type: Article

References (15)

1. Halberstadt AL: The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 1995;18:237-249.
2. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A: Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 1997;42:664-668.
3. Tsai G, Yang P, Chung LC, Lange N, Coyle JT: D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081-1089.
4. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT: D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156:1822-1825.
5. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH: Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 1992;256:1217-1221.
6. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
7. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT: Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-836.
8. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
9. Hong CJ, Chen JY, Chiu HJ, Sim CB: A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol 1997;12:123-130.
10. Faraone SV, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B, Hampe C, Zambuto CT, Schmitt K, Meyer J, Markel P, Lee H, Harkavy FJ, Kaufmann C, Cloninger CR, Tsuang MT: Genome scan of European-American schizophrenia pedigrees: Results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet 1998;81:290-295.
11. Ohtsuki T, Sakurai K, Dou H, Toru M, Yamakawa-Kobayashi K, Arinami T: Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol Psychiatry 2001;6:211-216.
12. Nishiguchi N, Shirakawa O, Ono H, Hashimoto T, Maeda K: Novel polymorphism in the gene region encoding the carboxyl-terminal intracellular domain of the NMDA receptor 2B subunit: Analysis of association with schizophrenia. Am J Psychiatry 2000;157:1329-1331.
13. Schito AM, Pizzuti A, Di Maria E, Schenone A, Ratti A, Defferrari R, Bellone E, Mancardi GL, Ajmar F, Mandich P: mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit. Neurosci Lett 1997;239:49-53.
14. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ: Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet 2001;11:219-222.
15. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW: Pharmacogenetic prediction of clozapine response. Lancet 2000;355:1615-1616.